Evidence map›Paper›PMID 35083584›Full record

ArticleAnnals of biomedical engineering2022

Modeling of Tumor Growth with Input from Patient-Specific Metabolomic Data.

Hunter A Miller, John Lowengrub, Hermann B Frieboes

Open access · greenAbstract read
In one paragraph

Article in Annals of biomedical engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Hunter A MillerDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA.
John LowengrubDepartment of Mathematics, University of California, Irvine, CA, USA.
Hermann B FrieboesDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA. hbfrie01@louisville.edu.ORCID http://orcid.org/0000-0001-5959-4286
University of Louisville · USUniversity of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Shared Resource Core: Single Cell AnalysisU54CA217378 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI LANDER, ARTHUR D · 2018 to 2022
$9.7M
Integrated framework to predict chemotherapy response post lung tumor resectionR15CA203605 · NCI · UNIVERSITY OF LOUISVILLE · PI FRIEBOES, HERMANN · 2016 to 2016
$462k
national science foundation DMS-1714973NCI NIH HHS P30 CA062203NCI NIH HHS R15 CA203605NCI NIH HHS R15CA203605NCI NIH HHS U54 CA217378NIH HHS 1U54CA217378-01A1NIH HHS P30CA062203simons foundation 594598QN
6 · The paper itself

Abstract

Advances in omic technologies have provided insight into cancer progression and treatment response. However, the nonlinear characteristics of cancer growth present a challenge to bridge from the molecular- to the tissue-scale, as tumor behavior cannot be encapsulated by the sum of the individual molecular details gleaned experimentally. Mathematical modeling and computational simulation have been traditionally employed to facilitate analysis of nonlinear systems. In this study, for the first time tumor metabolomic data are linked via mathematical modeling to the tumor tissue-scale behavior, showing the capability to mechanistically simulate cancer progression personalized to omic information obtainable from patient tumor core biopsy analysis. Generally, a higher degree of metabolic dysregulation has been correlated with more aggressive tumor behavior. Accordingly, key parameters influenced by metabolomic data in this model include tumor proliferation, vascularization, aggressiveness, lactic acid production, monocyte infiltration and macrophage polarization, and drug effect. The model enables evaluating interactions of interest between these parameters which drive tumor growth based on the metabolomic data. The results show that the model can group patients consistently with the clinically observed outcomes of response/non-response to chemotherapy. This modeling approach provides a first step towards evaluation of tumor growth based on tumor-specific metabolomic data.

Indexed as

Computer SimulationModels, TheoreticalNeovascularization, PathologicCell ProliferationHumansMetabolomicsNeoplasmsCancerComputational simulationMathematical modelingMetabolomicsPersonalized medicine

Identifiers

PMID35083584
PMCPMC9743982
OpenAlexW4210622929

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.